Clinically resectable acinar cell carcinoma of the pancreas: Is there a benefit to adjuvant systemic therapy? - 18/03/20
Abstract |
Background |
Prior studies of adjuvant systemic therapy in pancreatic acinar cell carcinoma have been underpowered.
Methods |
We queried the National Cancer Data Base to identify patients presenting with resectable (clinical stage I and II) acinar cell carcinoma between 2004 and 2015. Multivariable Cox Regression was used to evaluate the association between overall survival and systemic therapy.
Results |
298 patients met inclusion criteria: 38 received no treatment; 60 received systemic therapy alone; 84 received surgical resection alone; 116 underwent resection followed by adjuvant systemic therapy. On univariate analysis, resection was associated with a survival benefit compared to no treatment and systemic therapy alone (3-year overall survival: 57% vs. 26%, p < 0.001). On Cox analysis, use of adjuvant therapy was associated with a survival benefit compared to resection alone (HR 0.54, 95% CI: 0.33–0.89).
Conclusions |
Adjuvant therapy is associated with a significant survival benefit in patients with resectable acinar cell carcinoma.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Resection for ACC is associated with a survival benefit compared to no resection. |
• | Adjuvant therapy provides a survival benefit compared to resection alone for ACC. |
• | Lymph node positive status and margin positive status predict increased risk of death in nonmetastatic ACC. |
Plan
Vol 219 - N° 3
P. 522-526 - mars 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?